ArticleDiabetes, obesity & metabolism2026
Long-Term Follow-Up Incidence of Type 1 Diabetes and Associated Autoimmune Diseases in First-Degree Relatives.
Article in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Long-Term Follow-Up Incidence of Type 1 Diabetes and Associated Autoimmune Diseases in First-Degree Relatives.Diabetes, obesity & metabolism · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundFirst-degree relatives (FDRs) of individuals with type 1 diabetes (T1D) carry a significantly elevated risk of developing autoimmune diseases, including celiac disease (CD) and autoimmune thyroid disease (AITD). The DiaUnion 1.0 study aimed to characterize one-time autoantibodies, genetic risk profiles and long-term progression to T1D, CD or AITD in siblings of children newly diagnosed with T1D.
methodsBetween 1997 and 2010, 1427 Danish siblings provided plasma and DNA samples to the DanDiabKids biobank. Autoantibodies associated with T1D (GADA, IAA, IA2A, ZnT8A), CD (tTGA) and AITD (TPOA) were measured using ADAP technology and confirmed by radiobinding assays. Genotyping was performed to compute a T1D Genetic Risk Score (GRS). National registry data were used to track disease incidence up to year 2024.
resultsOut of 1417 screened samples, 7.8% were positive for islet autoantibodies (IAab), and 4.6% had multiple IAab. Disease incidence rate increased substantially with IAab positivity: 0.11 per 100 person-years in IAab-negative siblings, 2.46 in single-IAab positive and 8.10 in those with multiple IAab. Similarly, 1.97 per 100 person-years of tTGA-positive siblings developed CD, and 0.69 per 100 person-years of TPOA-positive individuals developed AITD. Higher GRS and HLA DR3/DR4 haplotypes were associated with autoantibody positivity (p < 0.0001).
conclusionsA single screening for T1D, CD and AITD autoantibodies combined with genetic risk scoring stratified long-term risk of clinically diagnosed autoimmune disease. These findings support further evaluation of targeted screening and follow-up strategies in FDRs to enable surveillance and potential early intervention before clinical onset.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.